CPT 87627 is referenced in 13 tracked payer policy changes from Harvard Pilgrim Health Care, Independence Blue Cross, and 6 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 87627 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Point32Health/Harvard Pilgrim Health Care is adding new CPT codes to four laboratory testing policies effective December 1, 2026. Billing teams must update their systems to recognize and process these newly covered codes: 0421U for colorectal cancer screening, 82950 for diabetes testing, 87638 for microorganism identification, and 87627, 0600U, 0601U, and 0610U for pathogen panel testing.
Independence Blue Cross updated laboratory services policy MA00.030aj to MA00.030am, effective 01/01/2026, adding 18 new CPT/HCPCS codes to the capitated laboratory program and removing 8 terminated codes. One procedure code (87812) was added to non-capitated hospital laboratory services. Billing teams must update systems to route claims for new codes to designated capitated laboratory sites and verify code status before processing claims.
Independence Blue Cross updated Medicare Advantage policy MA00.010av to MA00.010aw effective 01/01/2026, adding 39 new CPT/HCPCS codes across DME, laboratory, and radiology services, revising narratives for 8 existing codes, and terminating 23 codes. Billing teams must update systems to reflect these code additions, deletions, and narrative changes to ensure accurate reimbursement for PPO members.
Effective January 1, 2026, Independence Blue Cross Medicare Advantage updates the MA06.034v eviCore Lab Management policy with significant coding changes: 6 new procedure codes added to pre-service and prepayment review requirements, 7 codes added to prepayment-only review, 10 PLA codes deleted, and 47 existing clinical guidelines revised (19 substantively). Two new genetic testing guidelines for Hereditary Ataxia and Hereditary Connective Tissue/Thoracic Aortic Disease are added, requiring billing staff to update authorization workflows and code tracking immediately.
Independence Blue Cross updated policy 00.03.07ar to 00.03.07au effective 01/01/2026, adding 18 new CPT/HCPCS laboratory codes to the capitated laboratory program (Attachment A1) and removing 8 terminated codes, plus adding CPT 87812 to non-capitated outpatient hospital laboratory services (Attachment B2). Billing teams must update systems to route the newly added codes to designated capitated lab sites for HMO/HMO-POS members and ensure CPT 87812 is only billed to outpatient hospital labs under specific circumstances.
Effective January 1, 2026, Independence Blue Cross is updating its eviCore Lab Management policy with new procedure codes, revised clinical guidelines, and substantive medical necessity criteria changes. Six codes (0602U, 0611U, 0612U, 0613U, 81354, 81524) now require pre-service AND prepayment reviews; seven codes (87183, 87494, 87627, 0600U, 0605U, 0607U, 0608U) require prepayment reviews only; and 10 PLA codes are being deleted from coverage.
Humana Medicare Advantage revised its policy on multiplex pathogen identification panels for infectious disease, effective 11/02/2026. The policy confirms coverage of molecular syndromic panels (including bloodstream, gastrointestinal, respiratory, meningoencephalitis, urinary tract, and other infection panels) when ordered by treating physicians and medical necessity criteria are met, following applicable CMS LCD/LCA guidance by MAC jurisdiction. Billing teams must verify that claims include the correct CPT or HCPCS codes for the specific panel type and confirm the member's MAC jurisdiction to apply the correct LCD/LCA requirements.
Effective October 1, 2026, nucleic acid probe testing with or without quantification may be considered medically necessary for BK virus, cytomegalovirus, hepatitis B, hepatitis C, hepatitis D, HIV-1, HIV-2, human herpesvirus 6 and influenza virus. Respiratory pathogen panels with 12 or more targets are considered not medically necessary. Quantification for other microorganisms, hepatitis G testing, central nervous system pathogen panels, urinary tract infection panels, joint infection panels, endometrial pathogen panels, pathogen panels for surgical or chronic wounds and oral HPV testing are considered investigational.
Blue Cross Blue Shield of Massachusetts medical policy changes take effect October 1, 2026 across dermatology, hematology and oncology, laboratory, neurology, orthopedics, pharmacy, pulmonology, radiation oncology and urology policies. Prior authorization is required for hematopoietic cell transplantation for autoimmune diseases, now covering multiple sclerosis with criteria, and for radiopharmaceutical codes A9517 and A9530 through Carelon Medical Benefits Management. Carelon genetic testing and sleep program guideline changes take effect November 15, 2026, and Category III CPT codes stay non-covered unless a BCBSMA medical policy describes them as medically necessary.
Molecular syndromic infectious disease pathogen panel testing may be considered medically necessary when the individual has a clinical indication for infectious disease testing, it is clearly documented why evaluation for more than one pathogen by molecular testing is necessary for patient management, the results will impact clinical management in a manner already demonstrated in peer-reviewed literature to improve patient outcomes, and the testing is performed according to the intended use of the test. Respiratory panels of up to five pathogens (87631) and gastrointestinal panels of up to 5 targets (87505) may be considered medically necessary under the panel-specific criteria, while molecular panels for sexually transmitted infections, urinary tract infections, wounds, wellness, cerebrospinal fluid, bloodstream pathogens, stool, vaginal swabs, and antibiotic resistance are considered not medically necessary. Molecular-based panel testing for wound infections is considered not medically necessary, and CPT 0666U was added on 10/01/2026.
Medical Policy GT85, Identification of Microorganisms Using Nucleic Acid Probes, is effective October 1, 2026. Nucleic acid testing using a direct or amplified probe technique, with or without quantification, may be considered medically necessary for BK virus, cytomegalovirus, hepatitis B virus, hepatitis C virus, hepatitis D virus, HIV-1, HIV-2, human herpesvirus 6, and influenza virus. Respiratory pathogen panels with 12 or more targets are considered not medically necessary. Testing with quantification or semi-quantification for other microorganisms, hepatitis G virus testing, central nervous system pathogen panels, urinary tract infection pathogen panels, joint infection panels, endometrial pathogen panels, pathogen panels for surgical or chronic wounds, and oral HPV testing are considered investigational. The technique for quantification includes both amplification and direct probes, so simultaneous coding for quantification with either amplification or direct probes is not warranted. SARS-CoV-2 nucleic acid testing is addressed in a separate policy, COVID-19 Testing, Laboratory, Policy No. 74.
Effective for dates of service on or after January 1, 2026, Indiana Medicaid lists the new CPT, CDT and other HCPCS codes from the 2026 annual HCPCS update as either covered or noncovered, and shows whether each one requires prior authorization or NDC. Codes discontinued in the update are listed with alternate code considerations, and the source states that inclusion of an alternate code does not indicate IHCP coverage of that alternate code. The IHCP is awaiting the final posting of the CMS fee schedules that set pricing for these codes, and reimbursement amounts will be posted on the Professional Fee Schedule and Outpatient Fee Schedule once pricing is established.
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan published a list of medical policies that have been updated or newly added in August 2026. Several policies add or remove CPT codes, including CAM 329, CAM 303, CAM 181 and CAM 291. CAM 235 applies reimbursement based unit restrictions to codes 87798 and 87801.
Watch 87627
Get one email when a payer policy names 87627, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 87627
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 87627 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.